Printer Friendly

PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT

 PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING
 VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
 CAMBRIDGE, Mass., July 27 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) has named John Curling as vice president, international business development, the company announced today. A 23-year veteran of Pharmacia LKB (Uppsalla, Sweden), Curling was previously the president of Pharmacia's Process Division from 1984 to 1990. Prior to 1984, he held senior management positions in Pharmacia's Industrial Separations Group, which he formed in 1974. He previously spent seven years in technical services positions at Pharmacia. Curling joined Pharmacia in 1967.
 Curling will play an important role in executing the company's business strategy, including international sales and marketing and the opening of the company's German subsidiary. Curling will also work closely with PerSeptive Biosystems' Process Division, recently formed to provide resources dedicated to the application of the company's patented POROS(R) chromatography media to process- and manufacturing-scale purification of biopharmaceuticals.
 "John Curling has been instrumental in creating and growing the process-scale biochromatography business of the largest supplier to the biopharmaceutical industry," noted Noubar Afeyan, Ph.D., president and CEO of PerSeptive Biosystems. "His decision to join our company is a significant endorsement of our breakthrough separations technologies for biopharmaceutical developers from discovery through manufacturing. We are delighted to have his experience and knowledge to support our worldwide sales and marketing programs."
 Curling stated, "I believe that PerSeptive Biosystems has truly innovative technology in its Perfusion particle development, rational surface chemistry design and ImmunoDetection(tm) technologies applied to real-time process monitoring. The company has the potential to become a major player in both the analytical and industrial separations markets in the biopharmaceutical arena."
 Curing is the author of numerous publications in the field of blood plasma purification and industrial chromatography. He is also contributor to and editor of Methods of Plasma Protein Fractionation, and is currently on the editorial boards of Bioseparations and The Journal of Chemical Technology and Biotechnology.
 Curling is a member of the International Association for Biological Standardization and the International Society of Blood Transfusion. In recent years he has worked with both the World Health Organization and the government of India in connection with blood product policies and a blood plasma fractionation program.
 A graduate of University of Sussex (U.K.), Curling holds a B.S. degree in chemistry.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection and Rational Surface Design(tm).
 Perfusion Chromatography and POROS are registered trademarks and ImmunoDetection and Rational Surface Design are trademarks of the company.
 -0- 7/27/92
 /CONTACT: Robert A. Fein, vice president and chief financial officer, PerSeptive Biosystems, 617-621-1787, or Pam Haslam, vice president of Feinstein Partners, 617-577-8110, for PerSeptive Biosystems/
 (PBIO) CO: PerSeptive Biosystems ST: Massachusetts IN: MTC SU: PER


CN -- NE006 -- 3379 07/27/92 09:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1992
Words:512
Previous Article:INTERPUBLIC GROUP REPORTS RESULTS FOR SECOND QUARTER 1992
Next Article:GLENN F. TILTON APPOINTED PRESIDENT OF TEXACO EUROPE
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS ANNOUNCES THE EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 375,000 SHARES, COMPLETING ITS INITIAL PUBLIC OFFERING
PERSEPTIVE BIOSYSTEMS SUBMITS DRUG MASTER FILE WITH FDA COVERING POROS CHROMATOGRAPHY MEDIA
PERSEPTIVE BIOSYSTEMS NAMES HUBERT M. QUINN VICE PRESIDENT, CHEMICAL PRODUCTION
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS ANNOUNCE THE FORMATION OF PERISIS: A STRATEGIC ALLIANCE FOR OLIGONUCLEOTIDE MANUFACT. TECHNOLOGIES
PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES FILING OF REGISTRATION STATEMENT RELATING TO PERSEPTIVE TECHNOLOGIES II CORP.
PERSEPTIVE BIOSYSTEMS ADDS FORMER COO OF DIGITAL EQUIPMENT CORPORATION TO BOARD OF DIRECTORS
PERSEPTIVE BIOSYSTEMS CREATES NEW EXECUTIVE POST
PERSEPTIVE BIOSYSTEMS COMMENCES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters